Clinical manifestation of gadodiamide-related nephrogenic systemic fibrosis

Marckmann, Peter; Skov, Lone; Rossen, Kristian; Thomsen, Henrik S.

doi:10.5414/cnp69161

Cited by 60 publications

(43 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…NSF is undeniably a rare but devastating disease, presenting with a spectrum of clinical and histopathologic manifestations (2,3). It is associated with increased tissue deposition of collagen in the skin, subcutaneous fascia, striated muscles, joints, diaphragm, lungs, liver, and myocardium (4).…”

Section: Discussionmentioning

confidence: 99%

Low Risk for Nephrogenic Systemic Fibrosis in Nondialysis Patients Who Have Chronic Kidney Disease and Are Investigated with Gadolinium-Enhanced Magnetic Resonance Imaging

Chrysochou

Power²,

Shurrab³

et al. 2010

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Background and objectives: During the past decade, nephrogenic systemic fibrosis (NSF) has been reported in patients who have severe renal impairment and have been exposed to a gadolinium (Gd)-based contrast agent during magnetic resonance imaging (MRI). As a result of positive reporting bias, many suitable patients with chronic kidney disease (CKD) are being denied a highly important form of investigation that can be safely undertaken. We analyzed the safety of Gd-MRI in patients with CKD and varying levels of estimated GFR (eGFR).Design Conclusions: In this study, no patients developed NSF during extended follow-up, even after multiple Gd doses in some. Gd-MRI can be safely undertaken in the majority of patients with CKD, but caution is merited for dialysis patients and those with acute kidney injury, with relative caution for predialysis patients with stage 5 CKD.

show abstract

Section: Discussionmentioning

confidence: 99%

Low Risk for Nephrogenic Systemic Fibrosis in Nondialysis Patients Who Have Chronic Kidney Disease and Are Investigated with Gadolinium-Enhanced Magnetic Resonance Imaging

Chrysochou

Power²,

Shurrab³

et al. 2010

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

“…The odds ratios for end-stage renal disease patients to develop systemic fibrosis after single, label doses of gadodiamide may range from 22 (12) to 32.5 (70). Curiously, the onset to the disease after exposure varies immensely, ranging from 24 h to several years (43,70,71,73).…”

Section: Contrast Dosementioning

confidence: 99%

Pathophysiology of gadolinium-associated systemic fibrosis

Wagner

Drel

Gorin

2016

American Journal of Physiology-Renal Physiology

View full text Add to dashboard Cite

show abstract

“…These scores have been adapted from those published by Marckmann et al 16 in 2008. Patient interviews were structured to assess the presence or absence of pain, itching, skin discoloration, skin stiffness, swelling of extremities, loss of physical abilities, sensory symptoms, hair loss, gastrointestinal discomfort, eye symptoms, pulmonary symptoms, or insomnia within the first 2 months after Gd exposure (symptoms count ranging from 0-12).…”

Section: B-blocker Usementioning

confidence: 99%